Home > Compound List > Product Information
Aprepitant_Molecular_structure_CAS_170729-80-3)
Click picture or here to close

Aprepitant

Catalog No. DB00673 Name DrugBank
CAS Number 170729-80-3 Website http://www.ualberta.ca/
M. F. C23H21F7N4O3 Telephone (780) 492-3111
M. W. 534.4266624 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 555

SYNONYMS

IUPAC name
5-{[(2S,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-2,3-dihydro-1H-1,2,4-triazol-3-one
IUPAC Traditional name
emend
Brand Name
Emend
Synonyms
MK-869
MK-0517
aprepitant

DATABASE IDS

CAS Number 170729-80-3

PROPERTIES

Hydrophobicity(logP) 4.5
Solubility Practically insoluble

DETAILS

Description (English)
Item Information
Drug Groups approved; investigational
Description Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).
Indication For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin (in combination with other antiemetic agents).
Pharmacology Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).
Affected Organisms
Humans and other mammals
Biotransformation Aprepitant is metabolized primarily by CYP3A4 with minor metabolism by CYP1A2 and CYP2C19. Seven metabolites of aprepitant, which are only weakly active, have been identified in human plasma.
Absorption The mean absolute oral bioavailability of aprepitant is approximately 60 to 65%.
Half Life 9-13 hours
Protein Binding >95%
Elimination Aprepitant is eliminated primarily by metabolism; aprepitant is not renally excreted. Aprepitant is excreted in the milk of rats. It is not known whether this drug is excreted in human milk.
Distribution * 70 L
Clearance * Apparent plasma cl=62-90 mL/min
External Links
Wikipedia
RxList
Drugs.com

REFERENCES